Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mindset Pharma Inc. (MSSTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3632+0.0685 (+23.26%)
At close: 03:06PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2947
Open0.3251
BidN/A x N/A
AskN/A x N/A
Day's Range0.2976 - 0.3640
52 Week Range0.2335 - 0.7573
Volume33,811
Avg. Volume23,905
Market Cap31.927M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.02
  • GlobeNewswire

    Mindset Pharma Provides Strategic Intellectual Property License to Cybin

    Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business StrategyTORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced an exclusive licensing agreement for Cybin Inc. (N

  • GlobeNewswire

    Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

    TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that the Company has received Scientific Advice from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) on a range of points to finalize its P

  • GlobeNewswire

    Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries

    TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced the filing of 16 different national applications for the protection of one of four of the Company’s key Families of novel, next-genera

Advertisement
Advertisement